Recognizing the Effects and Disparities of Pediatric Hidradenitis Suppurativa
In 2015, hidradenitis suppurativa (HS) was deemed a rare disease that was reported to affect fewer than 200 000 adults in the US, thus allowing adalimumab (Humira; AbbVie) to gain orphan drug approval for the treatment of moderate to severe disease in adults.1 Three years later in 2018, adalimumab w...
Gespeichert in:
| Veröffentlicht in: | Archives of dermatology (1960) 2021-04, Vol.157 (4), p.379-380 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 380 |
|---|---|
| container_issue | 4 |
| container_start_page | 379 |
| container_title | Archives of dermatology (1960) |
| container_volume | 157 |
| creator | Kirby, Joslyn S Zaenglein, Andrea L |
| description | In 2015, hidradenitis suppurativa (HS) was deemed a rare disease that was reported to affect fewer than 200 000 adults in the US, thus allowing adalimumab (Humira; AbbVie) to gain orphan drug approval for the treatment of moderate to severe disease in adults.1 Three years later in 2018, adalimumab was granted orphan drug approval for moderate to severe HS in adolescents (age 12-17 years), a group thought to be even less frequently affected by HS compared with adults.1 However, in the same year, Ingram et al2 reported updated epidemiological data on the prevalence of HS, with an estimated overall prevalence of HS at 0.77% in a Western population. The data by Ingram et al2 confirmed the experience of many dermatologists, that HS is not uncommon, but rather unseen. |
| doi_str_mv | 10.1001/jamadermatol.2020.5434 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2493000973</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ama_id>2776778</ama_id><sourcerecordid>2522847748</sourcerecordid><originalsourceid>FETCH-LOGICAL-a358t-d169fc2e62c39dab1a0555f2e32cba1e0db2de1bea274db6ed67783236765e9d3</originalsourceid><addsrcrecordid>eNpdkE1LAzEQhoMottT-AQ9lwYuXrfnaZPcotVpBUfw4h-xmtqZ0P0x2Bf31prYWMZcJzPMOMw9CE4KnBGNysdKVNuAq3TXrKcUUTxPO-AEaUiLSWOCUH-7_Ih2gsfcrHF6KMWfkGA0YEzThkgzR_RMUzbK2X7ZeRt0bRPOyhKLzka5NdGV9q53tLPioKaNHMFZ3zhbRwhoXNqhDy0fPfdv2Tnf2Q5-go1KvPYx3dYRer-cvs0V893BzO7u8izVL0i42RGRlQUHQgmVG50TjJElKCowWuSaATU4NkBw0ldzkAoyQMmWUCSkSyAwbofPt3NY17z34TlXWF7Be6xqa3ivKMxbuzSQL6Nk_dNX0rg7bKZpQmnIpeRoosaUK13jvoFSts5V2n4pgtXGu_jpXG-dq4zwEJ7vxfV6B2cd-DQfgdAuE_L5Lpfy56Bv754kJ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2522847748</pqid></control><display><type>article</type><title>Recognizing the Effects and Disparities of Pediatric Hidradenitis Suppurativa</title><source>American Medical Association Journals</source><creator>Kirby, Joslyn S ; Zaenglein, Andrea L</creator><creatorcontrib>Kirby, Joslyn S ; Zaenglein, Andrea L</creatorcontrib><description>In 2015, hidradenitis suppurativa (HS) was deemed a rare disease that was reported to affect fewer than 200 000 adults in the US, thus allowing adalimumab (Humira; AbbVie) to gain orphan drug approval for the treatment of moderate to severe disease in adults.1 Three years later in 2018, adalimumab was granted orphan drug approval for moderate to severe HS in adolescents (age 12-17 years), a group thought to be even less frequently affected by HS compared with adults.1 However, in the same year, Ingram et al2 reported updated epidemiological data on the prevalence of HS, with an estimated overall prevalence of HS at 0.77% in a Western population. The data by Ingram et al2 confirmed the experience of many dermatologists, that HS is not uncommon, but rather unseen.</description><identifier>ISSN: 2168-6068</identifier><identifier>EISSN: 2168-6084</identifier><identifier>DOI: 10.1001/jamadermatol.2020.5434</identifier><identifier>PMID: 33625471</identifier><language>eng</language><publisher>United States: American Medical Association</publisher><subject>Epidemiology ; Health disparities ; Health risks ; Monoclonal antibodies ; Pediatrics ; Rare diseases ; Side effects ; Skin diseases ; Teenagers</subject><ispartof>Archives of dermatology (1960), 2021-04, Vol.157 (4), p.379-380</ispartof><rights>Copyright American Medical Association Apr 2021</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a358t-d169fc2e62c39dab1a0555f2e32cba1e0db2de1bea274db6ed67783236765e9d3</citedby><cites>FETCH-LOGICAL-a358t-d169fc2e62c39dab1a0555f2e32cba1e0db2de1bea274db6ed67783236765e9d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://jamanetwork.com/journals/jamadermatology/articlepdf/10.1001/jamadermatol.2020.5434$$EPDF$$P50$$Gama$$H</linktopdf><linktohtml>$$Uhttps://jamanetwork.com/journals/jamadermatology/fullarticle/10.1001/jamadermatol.2020.5434$$EHTML$$P50$$Gama$$H</linktohtml><link.rule.ids>64,314,780,784,3339,27923,27924,76260,76263</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33625471$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kirby, Joslyn S</creatorcontrib><creatorcontrib>Zaenglein, Andrea L</creatorcontrib><title>Recognizing the Effects and Disparities of Pediatric Hidradenitis Suppurativa</title><title>Archives of dermatology (1960)</title><addtitle>JAMA Dermatol</addtitle><description>In 2015, hidradenitis suppurativa (HS) was deemed a rare disease that was reported to affect fewer than 200 000 adults in the US, thus allowing adalimumab (Humira; AbbVie) to gain orphan drug approval for the treatment of moderate to severe disease in adults.1 Three years later in 2018, adalimumab was granted orphan drug approval for moderate to severe HS in adolescents (age 12-17 years), a group thought to be even less frequently affected by HS compared with adults.1 However, in the same year, Ingram et al2 reported updated epidemiological data on the prevalence of HS, with an estimated overall prevalence of HS at 0.77% in a Western population. The data by Ingram et al2 confirmed the experience of many dermatologists, that HS is not uncommon, but rather unseen.</description><subject>Epidemiology</subject><subject>Health disparities</subject><subject>Health risks</subject><subject>Monoclonal antibodies</subject><subject>Pediatrics</subject><subject>Rare diseases</subject><subject>Side effects</subject><subject>Skin diseases</subject><subject>Teenagers</subject><issn>2168-6068</issn><issn>2168-6084</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpdkE1LAzEQhoMottT-AQ9lwYuXrfnaZPcotVpBUfw4h-xmtqZ0P0x2Bf31prYWMZcJzPMOMw9CE4KnBGNysdKVNuAq3TXrKcUUTxPO-AEaUiLSWOCUH-7_Ih2gsfcrHF6KMWfkGA0YEzThkgzR_RMUzbK2X7ZeRt0bRPOyhKLzka5NdGV9q53tLPioKaNHMFZ3zhbRwhoXNqhDy0fPfdv2Tnf2Q5-go1KvPYx3dYRer-cvs0V893BzO7u8izVL0i42RGRlQUHQgmVG50TjJElKCowWuSaATU4NkBw0ldzkAoyQMmWUCSkSyAwbofPt3NY17z34TlXWF7Be6xqa3ivKMxbuzSQL6Nk_dNX0rg7bKZpQmnIpeRoosaUK13jvoFSts5V2n4pgtXGu_jpXG-dq4zwEJ7vxfV6B2cd-DQfgdAuE_L5Lpfy56Bv754kJ</recordid><startdate>20210401</startdate><enddate>20210401</enddate><creator>Kirby, Joslyn S</creator><creator>Zaenglein, Andrea L</creator><general>American Medical Association</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20210401</creationdate><title>Recognizing the Effects and Disparities of Pediatric Hidradenitis Suppurativa</title><author>Kirby, Joslyn S ; Zaenglein, Andrea L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a358t-d169fc2e62c39dab1a0555f2e32cba1e0db2de1bea274db6ed67783236765e9d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Epidemiology</topic><topic>Health disparities</topic><topic>Health risks</topic><topic>Monoclonal antibodies</topic><topic>Pediatrics</topic><topic>Rare diseases</topic><topic>Side effects</topic><topic>Skin diseases</topic><topic>Teenagers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kirby, Joslyn S</creatorcontrib><creatorcontrib>Zaenglein, Andrea L</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Archives of dermatology (1960)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kirby, Joslyn S</au><au>Zaenglein, Andrea L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recognizing the Effects and Disparities of Pediatric Hidradenitis Suppurativa</atitle><jtitle>Archives of dermatology (1960)</jtitle><addtitle>JAMA Dermatol</addtitle><date>2021-04-01</date><risdate>2021</risdate><volume>157</volume><issue>4</issue><spage>379</spage><epage>380</epage><pages>379-380</pages><issn>2168-6068</issn><eissn>2168-6084</eissn><abstract>In 2015, hidradenitis suppurativa (HS) was deemed a rare disease that was reported to affect fewer than 200 000 adults in the US, thus allowing adalimumab (Humira; AbbVie) to gain orphan drug approval for the treatment of moderate to severe disease in adults.1 Three years later in 2018, adalimumab was granted orphan drug approval for moderate to severe HS in adolescents (age 12-17 years), a group thought to be even less frequently affected by HS compared with adults.1 However, in the same year, Ingram et al2 reported updated epidemiological data on the prevalence of HS, with an estimated overall prevalence of HS at 0.77% in a Western population. The data by Ingram et al2 confirmed the experience of many dermatologists, that HS is not uncommon, but rather unseen.</abstract><cop>United States</cop><pub>American Medical Association</pub><pmid>33625471</pmid><doi>10.1001/jamadermatol.2020.5434</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2168-6068 |
| ispartof | Archives of dermatology (1960), 2021-04, Vol.157 (4), p.379-380 |
| issn | 2168-6068 2168-6084 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2493000973 |
| source | American Medical Association Journals |
| subjects | Epidemiology Health disparities Health risks Monoclonal antibodies Pediatrics Rare diseases Side effects Skin diseases Teenagers |
| title | Recognizing the Effects and Disparities of Pediatric Hidradenitis Suppurativa |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T09%3A47%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recognizing%20the%20Effects%20and%20Disparities%20of%20Pediatric%20Hidradenitis%20Suppurativa&rft.jtitle=Archives%20of%20dermatology%20(1960)&rft.au=Kirby,%20Joslyn%20S&rft.date=2021-04-01&rft.volume=157&rft.issue=4&rft.spage=379&rft.epage=380&rft.pages=379-380&rft.issn=2168-6068&rft.eissn=2168-6084&rft_id=info:doi/10.1001/jamadermatol.2020.5434&rft_dat=%3Cproquest_cross%3E2522847748%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2522847748&rft_id=info:pmid/33625471&rft_ama_id=2776778&rfr_iscdi=true |